UNSPSC 51172129: Fenoverine

This classification denotes an antispasmotic agent with the molecular formula C26H25N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N274ZQ6PZJ, chemically known as 10h-phenothiazine, 10-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)acetyl)- but generally known as fenoverine, which bears US NIH Compound Identifier 72098. European Medicines Agency schedules Fenoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07580MIG.

UNSPSC 51172129 Fenoverine is a Commodity code capturing pharmaceutical products used in state and local criminal justice, corrections, and probation settings. The code sees activity in offender supervision and testing programs where state and local agencies procure drug screening and confirmation services paired with specimen collection logistics. Collin County Community Supervision and Corrections Department's September 2026 RFP for offender specimen collection and drug testing services exemplifies the scope: the county is soliciting staffing for two collection sites in the Dallas-Fort Worth region, operation of an Interactive Voice Response system for randomized testing notifications, immunoassay screening with LC/MS/MS or GC/MS confirmation, electronic result reporting, and alternative testing methodologies including oral fluid and hair analysis. The successful vendor must hold lab certification from SAMHSA, Texas Department of Public Safety, or CAP. Issuing bodies under this code include county corrections departments and community supervision agencies that manage probation caseloads and testing compliance for offenders under community-based sentences.

Recent activity centers in Texas, where Collin County posted RFP 2026-327 with proposals due July 23, 2026 (note: posted date of September 25, 2026 is later than due date, suggesting a correction or historical record). The contract scope encompasses approximately 25,031 annual tests across five-panel, six-panel, and ancillary test formats, with an estimated annual value of $600,000 and a two-year initial term commencing September 1, 2026, renewable for three additional one-year periods. Pricing is structured on a per-test basis across three service models: screening only, confirmation after screening, and screening with automatic confirmation of positives. Evaluation weight favors vendor qualifications (25 points), cost (30 points), and demonstrated understanding of the scope (30 points), with optional Phase 2 demonstrations worth up to 30 additional points. The county reserves the right to award the RFP in whole or in part to multiple vendors.